[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 14 of about 14
1. Sengupta S, Michener CM, Escobar P, Belinson J, Ganapathi R: Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion. Gynecol Oncol; 2008 May;109(2):226-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.
  • OBJECTIVES: To identify proteins unique to metastatic ovarian cancer and test their potential involvement in cell adhesion.
  • METHODS: We purified plasma membrane from paired metastatic and primary tumor tissues from patients with stage IIIC ovarian cancer.
  • Membrane proteins unique to metastases were identified by liquid chromatographic mass spectrometry (LC-MS).
  • The role of one of the identified proteins, ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1) in cell adhesion was determined in the presence of LPA using both over-expression and down regulation approaches.
  • OCIAD1 over-expression in HEY ovarian cancer cells increased LPA-induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin 10/11.
  • CONCLUSIONS: This is the first report that OCIAD1 is over-expressed in metastatic ovarian cancer tissues.
  • The effect of OCIAD1 on cell adhesion may be related to its function in ovarian cancer.
  • Failure of paclitaxel to affect ovarian cancer cell adhesion in presence of OCIAD1 raises the possibility of OCIAD1's role in tumor metastasis.
  • Ongoing studies using a mouse orthotopic LPA-dependent ovarian cancer metastasis model are focused on strategies to inhibit the potential role of OCIAD1 in tumor metastasis.
  • [MeSH-major] Adenocarcinoma / physiopathology. Neoplasm Proteins / metabolism. Ovarian Neoplasms / physiopathology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Adhesion / drug effects. Cell Line, Tumor. Collagen Type I / pharmacology. Down-Regulation. Female. Humans. Laminin / pharmacology. Lysophospholipids / pharmacology. Paclitaxel / pharmacology. Protein Isoforms / pharmacology. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328549.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Collagen Type I; 0 / Laminin; 0 / Lysophospholipids; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / ovarian cancer immuno-reactive antigen domain containing 1, human; 22002-87-5 / lysophosphatidic acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Kawashima T, Murakami H, Kanamori T, Nakamura Y: [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy]. Gan To Kagaku Ryoho; 2007 Mar;34(3):461-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
  • An exploratory laparotomy was performed and stage IIIc ovarian cancer was diagnosed.
  • These drugs have different mechanisms of action.
  • These results suggest that CPT-11+CDDP may be effective against recurrent ovarian cancer, which is difficult to treat due to its resistance to platinum drugs and taxane drugs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Drug Resistance, Neoplasm. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Bridged Compounds / pharmacology. CA-125 Antigen / blood. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Routes. Female. Humans. Laparotomy. Paclitaxel / pharmacology. Remission Induction. Taxoids / pharmacology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353644.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / CA-125 Antigen; 0 / Taxoids; 1605-68-1 / taxane; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Kobayashi K, Fujimoto S, Takahashi M, Mutou T, Toyosawa T, Ohtsuka Y, Ogasawara T: [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1726-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
  • Intraperitoneal hyperthermic chemoperfusion (IHCP) was performed on a stage IIIc ovarian cancer patient with massive ascites who had been chemotherapy resistant.
  • A 59-year-old woman with advanced ovarian cancer complained of massive refractory ascites after 2 years' history of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascitic Fluid / therapy. Cystadenocarcinoma, Serous / therapy. Drug Resistance, Neoplasm. Hyperthermia, Induced. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619504.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Shimura K, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Takahashi R, Hirai H, Sumikuma T, Ashihara E, Inaba T, Fujita N, Yasuda J, Nakagawa M: [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer]. Rinsho Ketsueki; 2001 Feb;42(2):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer].
  • A 40-year-old woman, who had suffered from AML (M1) in 1983, developed ovarian cancer (stage IIIc) in December 1996 after long-term remission.
  • She underwent surgical resection of the cancer, 10 courses of standard chemotherapy and tandem PBSCT (total dose: CBDCA 6,750 mg, CDDP 200 mg, CPA 16,000 mg, THP-ADR 450 mg).
  • As she had not received etoposide, this case was thought to have been therapy-related leukemia due to the platinum agents used for treating the ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / adverse effects. Cisplatin / adverse effects. Doxorubicin / analogs & derivatives. Leukemia, Myeloid / etiology. Neoplasms, Second Primary / etiology. Ovarian Neoplasms / drug therapy


5. Argon A, Aydiner A, Tas F, Saip P, Topuz E: Safety of paclitaxel in a patient with ovarian cancer and hyperbilirubinemia due to Rotor's syndrome. Gynecol Oncol; 2002 May;85(2):362-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of paclitaxel in a patient with ovarian cancer and hyperbilirubinemia due to Rotor's syndrome.
  • Treatment decision may be challenging in a cancer patient with Rotor's syndrome, since the majority of the antineoplastic agents are metabolized in the liver and excreted via the biliary system.
  • We report the first case of paclitaxel administration in a patient with ovarian cancer and elevated bilirubin levels due to Rotor's syndrome.
  • CASE: A 50-year-old woman with Rotor's syndrome had an exploratory laparotomy and was diagnosed to have stage IIIC epithelial ovarian cancer.
  • CONCLUSION: Paclitaxel appears to be safe to administer to cancer patients with functional hyperbilirubinemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperbilirubinemia / complications. Hyperbilirubinemia, Hereditary / complications. Ovarian Neoplasms / complications. Ovarian Neoplasms / drug therapy. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Jaundice.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2002 Elsevier Science (USA).
  • (PMID = 11972401.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Motl SE, Fausel C: Recurring chemotherapy-associated alopecia areata: case report and literature review. Pharmacotherapy; 2003 Jan;23(1):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 52-year-old woman with stage IIIC ovarian cancer and stage IA uterine cancer experienced recurring alopecia areata of her eyebrows, eyelashes, arms, legs, and pubic area beginning 5 months after completing chemotherapy with paclitaxel and carboplatin.
  • Alopecia is a well-recognized adverse event associated with chemotherapy; however, to our knowledge, this cyclic pattern of alopecia has not been reported in a patient with cancer.
  • Our report of a cancer survivor who experienced cyclic alopecia areata indicates that this condition may be related to autoimmune changes instigated by chemotherapy.

  • Genetic Alliance. consumer health - Alopecia Areata.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12523468.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 21
  •  go-up   go-down


7. Hasenburg A, Tong XW, Fischer DC, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan AL, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG: Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol; 2001 Dec;83(3):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.
  • OBJECTIVE: Patients with recurrent ovarian cancer were treated intraperitoneally (ip) with a replication-deficient recombinant adenovirus (ADV) containing the herpes simplex virus thymidine kinase gene.
  • METHODS: Ten patients with stage IIIc epithelial ovarian cancer underwent secondary debulking to < or =0.5 cm residual tumor.
  • Patients pretreated with an average of three different chemotherapeutic drugs and two different chemotherapy regimens had a median overall survival (OS) of 18.5 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Genetic Therapy / methods. Ovarian Neoplasms / therapy. Thymidine Kinase / genetics. Topotecan / therapeutic use
  • [MeSH-minor] Acyclovir / pharmacokinetics. Acyclovir / therapeutic use. Adenoviridae / enzymology. Adenoviridae / genetics. Adult. Aged. Antiviral Agents / pharmacokinetics. Antiviral Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Second-Look Surgery


8. Samaritani R, Corrado G, Vizza E, Sbiroli C: Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer; 2007;7:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
  • BACKGROUND: Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.
  • CASE PRESENTATION: We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Palliative Care. Salvage Therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Colonic Neoplasms / complications. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Colostomy. Disease-Free Survival. Drug Administration Schedule. Drug Evaluation. Drug Resistance, Neoplasm. Epoetin Alfa. Erythropoietin / therapeutic use. Fatal Outcome. Female. Follow-Up Studies. Hemorrhage / etiology. Humans. Intestinal Obstruction / etiology. Karnofsky Performance Status. Laparotomy. Ovariectomy. Paclitaxel / administration & dosage. Peritoneal Neoplasms / secondary. Recombinant Proteins. Topotecan / administration & dosage. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / secondary. Vitamins / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):427-36 [11693902.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):12-5 [11863092.001]
  • [Cites] Lancet Oncol. 2001 Dec;2(12):733-40 [11902515.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):179-86 [12063566.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Nov;2(11):562-77 [16270097.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22 [14561896.001]
  • [Cites] Minerva Ginecol. 2004 Feb;56(1):81-9 [14973412.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):939-52 [15557593.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):916-23 [15907981.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6938-43 [12460910.001]
  • (PMID = 17433113.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Vitamins; 11096-26-7 / Erythropoietin; 64FS3BFH5W / Epoetin Alfa; 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1863429
  •  go-up   go-down


9. Burgert JM: Intraosseous infusion of blood products and epinephrine in an adult patient in hemorrhagic shock. AANA J; 2009 Oct;77(5):359-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraosseous infusion of blood products and epinephrine in an adult patient in hemorrhagic shock.
  • Her medical history included recurrent stage IIIC ovarian cancer.
  • The patient rapidly decompensated despite blood products administered through the patient's implanted medication port.
  • While peripheral intravenous (IV) access was sought, her condition further deteriorated.
  • Crystalloid and colloid fluids, blood products, and drugs were administered via the IO route, stabilizing the patient's condition during the central access procedure.
  • Intraosseous infusion is a valuable and underutilized technique in managing patients in hemorrhagic shock with poor IV access.
  • [MeSH-major] Blood Transfusion / instrumentation. Epinephrine / administration & dosage. Infusions, Intraosseous / methods. Jejunostomy / adverse effects. Shock, Hemorrhagic / therapy. Vasoconstrictor Agents / administration & dosage
  • [MeSH-minor] Aged. Anesthesia Recovery Period. Catheterization, Central Venous / adverse effects. Catheterization, Peripheral / adverse effects. Equipment Failure. Female. Hematemesis / etiology. Humans. Nurse Anesthetists. Ovarian Neoplasms / complications. Patient Selection. Postoperative Care / methods. Resuscitation / instrumentation. Tibia

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911645.001).
  • [ISSN] 0094-6354
  • [Journal-full-title] AANA journal
  • [ISO-abbreviation] AANA J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; YKH834O4BH / Epinephrine
  •  go-up   go-down


10. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg; 2003 Dec;197(6):955-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
  • BACKGROUND: Results of IDS (after three to four courses of induction chemotherapy) were compared with PDS followed by chemotherapy in patients treated for advanced stage ovarian cancer (stage IIIC or IV).
  • CONCLUSIONS: Survival rates were similar in patients with advanced stage ovarian cancer who underwent IDS or PDS.
  • IDS can be safely used in unresectable advanced stage ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Paclitaxel / administration & dosage. Platinum Compounds / administration & dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14644284.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Platinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Ceelen WP, Påhlman L, Mahteme H: Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res; 2007;134:195-214
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The superiority of combined ip and intravenous chemotherapy over intravenous chemotherapy alone has been established in randomized trials in stage IIIc ovarian cancer patients.
  • Intraoperative ip cytotoxic therapy results in a definite pharmacological advantage, since high peritoneal concentrations are achieved with limited systemic absorption.
  • Among the cytotoxic agents currently used, the pharmacodynamic aspects of the platinum compounds are the best studied both with and without associated hyperthermia.
  • Newer agents such as the taxanes and the camptothecins appear promising for ip chemoperfusion during or immediately after surgery.
  • Pharmacodynamic aspects of HIPEC needing further preclinical study-including mathematical modeling - are the establishment of tumour tissue penetration of the newer agents and its relation to hyperthermia, the definition of the relative contribution of direct penetration versus vascular supply by absorbed drug, and the efficacy of combined ip and intravenous regimens.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Infusions, Parenteral / methods. Neoplasms / metabolism. Peritoneum / metabolism
  • [MeSH-minor] Animals. Humans. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633055.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 79
  •  go-up   go-down


12. Komiyama S, Mizusawa Y, Onouchi M, Takehara K, Suzuki A, Mikami M: Effective weekly docetaxel for recurrent ovarian cancer: A case report. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective weekly docetaxel for recurrent ovarian cancer: A case report.
  • We experienced a case of recurrent ovarian cancer that responded to weekly docetaxel.
  • The patient had stage IIIC ovarian cancer (poorly differentiated serous adenocarcinoma).
  • This patient demonstrates the effectiveness of weekly docetaxel as salvage chemotherapy for recurrent ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Cystadenocarcinoma, Serous / therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / therapy. Taxoids / administration & dosage
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Palliative Care

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675355.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


13. Zylberberg B, Dormont D, Madelenat P, Daraï E: First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol; 2004;25(3):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
  • OBJECTIVES: To determine the feasibility, toxicity and efficacy of a first-line combination of intraperitoneal (i.p.) paclitaxel and cisplatin and intravenous (i.v.) ifosfamide in untreated patients with Stage IIIc ovarian cancer after cytoreduction or biopsies only.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Carcinoma / drug therapy. Carcinoma / mortality. Carcinoma / pathology. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Drug Administration Schedule. Female. France. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15171311.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


14. Zhao XD, Zhang Y, He SR, Yang L: [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma]. Ai Zheng; 2005 Dec;24(12):1542-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
  • BACKGROUND & OBJECTIVE: The first-line adjuvant chemotherapy regimens of ovarian cancer mainly include TC (paclitaxel combined with carboplatin) and PC (cisplatin combined with cyclophosphamide) protocols.
  • This study was to investigate the correlation of P53 expression to treatment outcome of ovarian cancer patients received the above 2 protocols, and explore the predictive value of P53 expression in selecting chemotherapy regimen.
  • METHODS: Records of 53 patients with advanced epithelial ovarian cancer (stage IIIc), treated with TC or PC regimen, were analyzed retrospectively.
  • CONCLUSIONS: P53 detection may play a role in selecting first-line chemotherapy for advanced epithelial ovarian cancer patients: TC regimen is preference for P53-positive patients, PC regimen may be a choice for P53-negative patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Middle Aged. Paclitaxel / administration & dosage. Predictive Value of Tests. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351810.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement